EGRX Eagle Pharmaceuticals, Inc.

90.17
+3  (3%)
Previous Close 87.18
Open 87.49
Price To book 8.83
Market Cap 1.37B
Shares 15,227,000
Volume 263,777
Short Ratio 14.66
Av. Daily Volume 238,789

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 30, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
PDUFA date under priority review July 23, 2017.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. 15 companies with outsized sales growth and widening profit margins
  2. FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke
  3. 3 Top Biotech Stocks to Buy in 2017
  4. Eagle Pharma Cancer Drug Secures New Patents
  5. Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka
  6. Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors
  7. New Strong Sell Stocks for March 6th
  8. Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  9. Edited Transcript of EGRX earnings conference call or presentation 1-Mar-17 1:30pm GMT
  10. Eagle Pharmaceuticals posts 4Q profit
  11. Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
  12. Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA
  13. MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
  14. Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka
  15. Eagle Pharmaceuticals Announces New Patents Issued for Bendeka
  16. Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017
  17. Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference
  18. Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)
  19. Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
  20. Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA